Paul Wilson is a scientist and economist working on global health policy. Some of his recent projects have focused on malaria drug subsidies, vaccine financing, and India's role in developing new drugs and vaccines for neglected diseases. He has also worked on international AIDS policy and is the lead author of the UN Millennium Project report Combating AIDS in the Developing World. Currently a consultant to NGOs and international organizations, Paul has been Director of Policy Analysis at the International AIDS Vaccine Initiative and Associate Director of the Earth Institute at Columbia University. Before moving to Columbia to work on global health policy, Dr. Wilson held research positions at Harvard, Rockefeller University, and Cornell Medical College, where he was Assistant Professor of Cell Biology. He has degrees in Zoology, Economics, and Physics. At the Mailman School, Paul and his colleague Ahmed Shelbaya teach Priorities in Global Health, a survey course for Masters students pursuing the Global Health certificate.
PhD, 1990, University of California at Berkeley
MSc, 1982, London School of Economics
BA, 1980, Princeton
Areas of Expertise
Select Global Activities
The economics of malaria elimination (for PATH MACEPA), Ethiopia, Kenya, Senegal, Zambia: I am helping PATH to understand the economics of malaria control and elimination in four African countries where they are working: Zambia, Kenya, Ethiopia, and Senegal. In collaboration with mathematical modelers, we are trying to determine which combinations of malaria control interventions might be sufficient in particular settings to eliminate malaria and prevent its reintroduction, and what these interventions would cost. This analysis will help countries make decisions about pursuing elimination and decide on the best path to this goal
An economic case for new insecticide development for malaria control: I am beginning a project with the International Vector Control Consortium to compare the costs of developing new insecticides for malaria control with the economic and public health costs of failing to do so, given the growing resistance of malaria-transmitting mosquitoes to the insecticides now in use.
Consultant to the Drugs for Neglected Diseases Initiative and the Gates Foundation on financing development of new drugs and vaccines for neglected diseases
Hecht, R., Wilson, P. & Palriwala, M. Improving Health R&D Financing for Developing Countries: A Menu of Innovative Policy Options Health Affairs 28 974-85 2009
Wilson, P. & Hecht, R. Financing of vaccine R&D gaps and opportunities for innovation Global Forum Update on Research for Health 4 88-93 2007
Hirshhorn, L. R., Oguda, L., Fullem, A., Dreesch, N. & Wilson, P. Estimating health workforce needs for antiretroviral therapy in resource-limited settings Human Resources for Health 4 1 2006
Ruxin, J., Paluzzi, J. E., Wilson, P. A., Tozan, Y., Kruk, M. & Teklehaimanot, A. Emerging consensus in HIV/AIDS, malaria, tuberculosis, and access to essential medicines Lancet 365 618-621 2005
UN Millennium Project [P.A. Wilson, lead author] Task Force on HIV/AIDS, Malaria, TB, and Access to Essential Medicines, Working Group on HIV/AIDS 2005